| Title |
Prevention of chemotherapy-induced neutropenia by special honey intake
|
|---|---|
| Published in |
Medical Oncology, January 2006
|
| DOI | 10.1385/mo:23:4:549 |
| Pubmed ID | |
| Authors |
Jamal Zidan, Lika Shetver, Anthony Gershuny, Amira Abzah, Sigalit Tamam, Moshe Stein, Eitan Friedman |
| Abstract |
Febrile neutropenia is a serious side effect of chemotherapy. Colony-stimulating factors (CSFs) are used for primary and secondary treatment in patients with grade 4 neutropenia. The use of CSFs is expensive and accompanied by side effects. In the current study, Life-Mel Honey (LMH) was administered to prevent neutropenia and to reduce the need for CSFs in patients treated with chemotherapy. Thirty cancer patients receiving chemotherapy for primary or metastatic disease were included. All patients had grade 4 neutropenia and were treated with CSFs. The patients repeated the same chemotherapy schedule, with the addition of LMH for 5 d. Blood count was performed weekly. There was no recurrence of neutropenia after LMH intake and no need for treatment with CSFs in 12 (40%) of patients. Eighteen (60%) patients with LMH developed neutropenia grade 4 and were treated with CSFs (p=0.007). Hemoglobin levels remained >11 g/dL during LMH intake in 19 (64%) patients. Only three (10%) patients had thrombocytopenia. Eight (32%) patients reported improvement in quality of life. The use of LMH in patients who are at high risk of developing neutropenia as a result of chemotherapy decreases the risk of pancytopenia and the need for CSFs. LMH is inexpensive, has no side effects, and is easy to administer. |
X Demographics
The data shown below were collected from the profiles of 7 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | 14% |
| United States | 1 | 14% |
| Saudi Arabia | 1 | 14% |
| Bahrain | 1 | 14% |
| Kuwait | 1 | 14% |
| Unknown | 2 | 29% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 7 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 29 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | 3% |
| Portugal | 1 | 3% |
| Unknown | 27 | 93% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 6 | 21% |
| Other | 3 | 10% |
| Student > Doctoral Student | 3 | 10% |
| Researcher | 3 | 10% |
| Student > Master | 3 | 10% |
| Other | 6 | 21% |
| Unknown | 5 | 17% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 8 | 28% |
| Agricultural and Biological Sciences | 5 | 17% |
| Biochemistry, Genetics and Molecular Biology | 3 | 10% |
| Nursing and Health Professions | 3 | 10% |
| Chemical Engineering | 1 | 3% |
| Other | 3 | 10% |
| Unknown | 6 | 21% |
Attention Score in Context
This research output has an Altmetric Attention Score of 9. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 04 September 2021.
All research outputs
#4,180,216
of 25,374,647 outputs
Outputs from Medical Oncology
#78
of 1,456 outputs
Outputs of similar age
#17,210
of 174,005 outputs
Outputs of similar age from Medical Oncology
#1
of 11 outputs
Altmetric has tracked 25,374,647 research outputs across all sources so far. Compared to these this one has done well and is in the 83rd percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,456 research outputs from this source. They receive a mean Attention Score of 3.3. This one has done particularly well, scoring higher than 94% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 174,005 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 90% of its contemporaries.
We're also able to compare this research output to 11 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 90% of its contemporaries.